55 research outputs found
Identification of MOR-Positive B Cell as Possible Innovative Biomarker (Mu Lympho-Marker) for Chronic Pain Diagnosis in Patients with Fibromyalgia and Osteoarthritis Diseases
Fibromyalgia (FM) diagnosis follows the American College of Rheumatology (ACR) criteria,
based on clinical evaluation and written questionnaires without any objective diagnostic tool. The lack
of specific biomarkers is a tragic aspect for FM and chronic pain diseases in general. Interestingly, the
endogenous opioid system is close to the immune one because of the expression of opioid receptors
on lymphocytes membrane. Here we analyzed the role of the Mu opioid receptor on B lymphocytes
as a specific biomarker for FM and osteoarthritis (OA) patients. We enrolled three groups of females:
FM patients, OA patients (chronic pain control group) and healthy subjects (pain-free negative control
group). We collected blood samples to apply immunophenotyping analysis. Written tests were
administrated for psychological analysis. Data were statistically analyzed. Final results showed
that the percentage of Mu-positive B cells were statistically lower in FM and OA patients than in
pain-free subjects. A low expression of Mu-positive B cell was not associated with the psychological
characteristics investigated. In conclusion, here we propose the percentage of Mu-positive B cells as a
biological marker for an objective diagnosis of chronic pain suffering patients, also contributing to the
legitimacy of FM as a truly painful disease
Posttranslational Nitration of Tyrosine Residues Modulates Glutamate Transmission and Contributes to N-Methyl-D-aspartate-Mediated Thermal Hyperalgesia
An observational study on chronic pain biomarkers in fibromyalgia and osteoarthritis patients:.which role for mu opioid receptor’s expression on NK cells.
The evaluation of chronic pain is challenging because of the lack of specific biomarkers. We identified the Mu opioid receptor-positive (Mu+) B cell percentage of expression, named Mu-Lympho-Marker (MLM), as a candidate marker for chronic pain in fibromyalgia (FM) and osteoarthritis (OA) patients. Here, we investigate the role of MLM on natural killer (NK) cells in the same patients. Twenty-nine FM and twelve OA patients were analyzed, and twenty-three pain-free subjects were considered as the control group. Blood samples were collected to perform immunophenotyping and Western blot analysis. Biological and clinical data were statistically analyzed. The final results showed that the percentage of NK cells expressing Mu was statistically lower in FM and OA patients than in pain-free subjects, as already demonstrated for B cells. A Western blot analysis was performed in order to detect NK cells' functional status. Moreover, the correlation analysis of MLM expression with pharmacological therapy did not show any significant results. In conclusion, here, we confirm the role of MLM as a suitable marker for chronic pain and underline NK cells as a new possible immune cell type involved in the "Mu opioid receptor reserve theory"
Superconductor-ferromagnet hybrids for non-reciprocal electronics and detectors
We review the use of hybrid thin films of superconductors and ferromagnets
for creating non-reciprocal electronic components and self-biased detectors of
electromagnetic radiation. We start by introducing the theory behind these
effects, as well as different possible materials that can be used in the
fabrication of these components. We proceed by discussing in detail the
fabrication and characterization of Al/EuS/Cu and EuS/Al/Co based detectors,
along with their noise analysis. We also indicate some routes for multiplexing
such self-biased detectors.Comment: 28 pages, 21 figure
Recommended from our members
Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021
BACKGROUND Regular, detailed reporting on population health by underlying cause of death is fundamental for public health decision making. Cause-specific estimates of mortality and the subsequent effects on life expectancy worldwide are valuable metrics to gauge progress in reducing mortality rates. These estimates are particularly important following large-scale mortality spikes, such as the COVID-19 pandemic. When systematically analysed, mortality rates and life expectancy allow comparisons of the consequences of causes of death globally and over time, providing a nuanced understanding of the effect of these causes on global populations. METHODS The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021 cause-of-death analysis estimated mortality and years of life lost (YLLs) from 288 causes of death by age-sex-location-year in 204 countries and territories and 811 subnational locations for each year from 1990 until 2021. The analysis used 56 604 data sources, including data from vital registration and verbal autopsy as well as surveys, censuses, surveillance systems, and cancer registries, among others. As with previous GBD rounds, cause-specific death rates for most causes were estimated using the Cause of Death Ensemble model-a modelling tool developed for GBD to assess the out-of-sample predictive validity of different statistical models and covariate permutations and combine those results to produce cause-specific mortality estimates-with alternative strategies adapted to model causes with insufficient data, substantial changes in reporting over the study period, or unusual epidemiology. YLLs were computed as the product of the number of deaths for each cause-age-sex-location-year and the standard life expectancy at each age. As part of the modelling process, uncertainty intervals (UIs) were generated using the 2·5th and 97·5th percentiles from a 1000-draw distribution for each metric. We decomposed life expectancy by cause of death, location, and year to show cause-specific effects on life expectancy from 1990 to 2021. We also used the coefficient of variation and the fraction of population affected by 90% of deaths to highlight concentrations of mortality. Findings are reported in counts and age-standardised rates. Methodological improvements for cause-of-death estimates in GBD 2021 include the expansion of under-5-years age group to include four new age groups, enhanced methods to account for stochastic variation of sparse data, and the inclusion of COVID-19 and other pandemic-related mortality-which includes excess mortality associated with the pandemic, excluding COVID-19, lower respiratory infections, measles, malaria, and pertussis. For this analysis, 199 new country-years of vital registration cause-of-death data, 5 country-years of surveillance data, 21 country-years of verbal autopsy data, and 94 country-years of other data types were added to those used in previous GBD rounds. FINDINGS The leading causes of age-standardised deaths globally were the same in 2019 as they were in 1990; in descending order, these were, ischaemic heart disease, stroke, chronic obstructive pulmonary disease, and lower respiratory infections. In 2021, however, COVID-19 replaced stroke as the second-leading age-standardised cause of death, with 94·0 deaths (95% UI 89·2-100·0) per 100 000 population. The COVID-19 pandemic shifted the rankings of the leading five causes, lowering stroke to the third-leading and chronic obstructive pulmonary disease to the fourth-leading position. In 2021, the highest age-standardised death rates from COVID-19 occurred in sub-Saharan Africa (271·0 deaths [250·1-290·7] per 100 000 population) and Latin America and the Caribbean (195·4 deaths [182·1-211·4] per 100 000 population). The lowest age-standardised death rates from COVID-19 were in the high-income super-region (48·1 deaths [47·4-48·8] per 100 000 population) and southeast Asia, east Asia, and Oceania (23·2 deaths [16·3-37·2] per 100 000 population). Globally, life expectancy steadily improved between 1990 and 2019 for 18 of the 22 investigated causes. Decomposition of global and regional life expectancy showed the positive effect that reductions in deaths from enteric infections, lower respiratory infections, stroke, and neonatal deaths, among others have contributed to improved survival over the study period. However, a net reduction of 1·6 years occurred in global life expectancy between 2019 and 2021, primarily due to increased death rates from COVID-19 and other pandemic-related mortality. Life expectancy was highly variable between super-regions over the study period, with southeast Asia, east Asia, and Oceania gaining 8·3 years (6·7-9·9) overall, while having the smallest reduction in life expectancy due to COVID-19 (0·4 years). The largest reduction in life expectancy due to COVID-19 occurred in Latin America and the Caribbean (3·6 years). Additionally, 53 of the 288 causes of death were highly concentrated in locations with less than 50% of the global population as of 2021, and these causes of death became progressively more concentrated since 1990, when only 44 causes showed this pattern. The concentration phenomenon is discussed heuristically with respect to enteric and lower respiratory infections, malaria, HIV/AIDS, neonatal disorders, tuberculosis, and measles. INTERPRETATION Long-standing gains in life expectancy and reductions in many of the leading causes of death have been disrupted by the COVID-19 pandemic, the adverse effects of which were spread unevenly among populations. Despite the pandemic, there has been continued progress in combatting several notable causes of death, leading to improved global life expectancy over the study period. Each of the seven GBD super-regions showed an overall improvement from 1990 and 2021, obscuring the negative effect in the years of the pandemic. Additionally, our findings regarding regional variation in causes of death driving increases in life expectancy hold clear policy utility. Analyses of shifting mortality trends reveal that several causes, once widespread globally, are now increasingly concentrated geographically. These changes in mortality concentration, alongside further investigation of changing risks, interventions, and relevant policy, present an important opportunity to deepen our understanding of mortality-reduction strategies. Examining patterns in mortality concentration might reveal areas where successful public health interventions have been implemented. Translating these successes to locations where certain causes of death remain entrenched can inform policies that work to improve life expectancy for people everywhere. FUNDING Bill & Melinda Gates Foundation
European Hophornbeam Biomass for Energy Application: Influence of Different Production Processes and Heating Devices on Environmental Sustainability
Environmental sustainability has recently shifted towards biodiversity protection via governmental and intergovernmental initiatives (e.g., the UN Millennium Ecosystem Assessment, MA). The life cycle assessment, the widespread method for assessing environmental sustainability, was not created to evaluate impacts on biodiversity. However, several authors recognize its ability to estimate biodiversity loss drivers (impact indices on land use change and ecosystem). The study aims to apply LCA to the forest sector, precisely to the wood–energy chain of Hophornbeam, to cover suggestions of the MA for the biodiversity impact assessment. Six different scenarios for stove (3) and fireplace (3) wood production were analyzed, evaluating two baselines and four alternative scenarios, including sensitivity analyses related to transport distances for the raw materials. The functional unit is 1 MJ of energy. The fireplace combustion scenarios are relatively more sustainable than the stove ones are (2.95–3.21% less). The global warming potential (around 3 g CO2 eq/MJ) is consistent with current European directives on the sustainability of biofuels and scientific literature. The scenarios showed similarities regarding the impact of the categories related to MA drivers. Although biodiversity is protected by limiting forest management, some authors argue that for some species (e.g., Hophornbeam), a rational tree felling could produce biofuels, increasing biodiversity
Quality Assessment and Classification of Feedstock for Bioenergy Applications Considering ISO 17225 Standard on Solid Biofuels
Biomass materials play a key role in the renewable energy market as they can serve as a suitable alternative to fossil fuels. However, the quality of the material entering bioenergy plants is often a cause of technical concern. Biomass quality assessment is crucial not only for energy characterization but also for environmental and operational aspects. The goal of this study is to characterize and classify the biomasses used by Italian power plants with reference to the quality classes stated by the ISO standard 17225:2021. A further objective is to verify the ability of the standard to classify heterogeneous and specific biomasses. In this study, more than 900 biomass samples were analyzed. The samples were collected from several Italian power plants with >5 MWe between 2010 and 2020, and the most important physical and chemical parameters were analyzed according to the international standards of reference. The results of the analyses were collected in a large dataset used for subsequent statistical analyses. Statistical analyses applied are Principal Component Analysis and Pearson correlation maps, which showed that the ash content is a fundamental and ideal parameter to assess the biomass quality. Results obtained demonstrate that herbaceous biomasses are of low quality mainly due to the high ash content; a relatively low ash content was found for woody biomasses
Endothelial Dysfunction and Extra-Articular Neurological Manifestations in Rheumatoid Arthritis
Rheumatoid arthritis (RA) is a chronic, systemic, inflammatory autoimmune disease that affects about 1% of the global population, with a female–male ratio of 3:1. RA preferably affects the joints, with consequent joint swelling and deformities followed by ankylosis. However, evidence has accumulated showing that patients suffering from RA can also develop extra-articular manifestations, including cardiovascular disease states, neuropathies, and multiorgan dysfunction. In particular, peripheral nerve disorders showed a consistent impact in the course of the disease (prevalence about 20%) mostly associated to vasculitis of the nerve vessels leading to vascular ischemia, axonal degeneration, and neuronal demyelination. The pathophysiological basis of this RA-associated microvascular disease, which leads to impairment of assonal functionality, is still to be better clarified. However, endothelial dysfunction and alterations of the so-called brain-nerve barrier (BNB) seem to play a fundamental role. This review aims to assess the potential mechanisms underlying the impairment of endothelial cell functionality in the development of RA and to identify the role of dysfunctional endothelium as a causative mechanism of extra-articular manifestation of RA. On the other hand, the potential impact of lifestyle and nutritional interventions targeting the maintenance of endothelial cell integrity in patients with RA will be discussed as a potential option when approaching therapeutic solutions in the course of the disease
Endothelial Dysfunction and Extra-Articular Neurological Manifestations in Rheumatoid Arthritis
Rheumatoid arthritis (RA) is a chronic, systemic, inflammatory autoimmune disease that affects about 1% of the global population, with a female–male ratio of 3:1. RA preferably affects the joints, with consequent joint swelling and deformities followed by ankylosis. However, evidence has accumulated showing that patients suffering from RA can also develop extra-articular manifestations, including cardiovascular disease states, neuropathies, and multiorgan dysfunction. In particular, peripheral nerve disorders showed a consistent impact in the course of the disease (prevalence about 20%) mostly associated to vasculitis of the nerve vessels leading to vascular ischemia, axonal degeneration, and neuronal demyelination. The pathophysiological basis of this RA-associated microvascular disease, which leads to impairment of assonal functionality, is still to be better clarified. However, endothelial dysfunction and alterations of the so-called brain-nerve barrier (BNB) seem to play a fundamental role. This review aims to assess the potential mechanisms underlying the impairment of endothelial cell functionality in the development of RA and to identify the role of dysfunctional endothelium as a causative mechanism of extra-articular manifestation of RA. On the other hand, the potential impact of lifestyle and nutritional interventions targeting the maintenance of endothelial cell integrity in patients with RA will be discussed as a potential option when approaching therapeutic solutions in the course of the disease
A Review of the Clinical and Therapeutic Implications of Neuropathic Pain
Understanding neuropathic pain presents several challenges, given the various mechanisms underlying its pathophysiological classification and the lack of suitable tools to assess its diagnosis. Furthermore, the response of this pathology to available drugs is still often unpredictable, leaving the treatment of neuropathic pain still questionable. In addition, the rise of personalized treatments further extends the ramified classification of neuropathic pain. While a few authors have focused on neuropathic pain clustering, by analyzing, for example, the presence of specific TRP channels, others have evaluated the presence of alterations in microRNAs to find tailored therapies. Thus, this review aims to synthesize the available evidence on the topic from a clinical perspective and provide a list of current demonstrations on the treatment of this disease
- …